RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Lymphoma drug trial halted after researchers fail to find safe dose
Disease control OngoingThis study aimed to test the safety and find the right dose of a new drug combination (tolinapant plus oral decitabine/cedazuridine) for adults with a rare and aggressive blood cancer that had returned or stopped responding to prior treatments. The trial was stopped early after t…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Phase: PHASE1 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
New drug trial offers hope for Tough-to-Treat blood cancer
Disease control OngoingThis study is testing an oral drug called valemetostat in adults whose peripheral T-cell lymphoma has come back or hasn't responded to prior treatments. The main goal is to see if the drug safely shrinks tumors and for how long. It includes 155 participants and focuses on measuri…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC